" class="no-js "lang="en-US"> Bio-Rad Launches CFX Duet Real-Time PCR System - Medtech Alert
Monday, October 07, 2024

Bio-Rad Launches CFX Duet Real-Time PCR System

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX Duet Real-Time PCR System to support researchers in developing singleplex and duplex quantitative PCR (qPCR) assays.

 

The CFX Duet System offers the robust thermal performance and proprietary, accurate optical shuttle system of Bio-Rad’s CFX Opus System, with thermal gradient functionality to enable optimization in fewer runs. The CFX Duet is a two-color system that is factory calibrated for common dyes and, without the need for passive reference dyes, allows the precise quantification of up to two targets in genotyping and multiple gene expression analyses. An additional fluorescence resonance energy transfer (FRET) mode supports protein melt analysis for basic protein characterization. The CFX Duet System utilizes CFX Maestro Software for easy experimental setup and analysis, and to deliver customized reports without exporting data to other programs.

 

“We are pleased to expand our portfolio of qPCR instruments with the CFX Duet System to help customers run singleplex and duplex assays with a software that matches the robust thermal capabilities of our premium CFX Opus formats.” said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. “The versatile CFX Duet System allows users to quickly get started with gene expression, genotyping, quantification and thermal gradient optimization, as well as protein characterization using FRET.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more